NovaBridge Biosciences (NBP) Receivables - Other (2018 - 2023)

NovaBridge Biosciences (NBP) has 6 years of Receivables - Other data on file, last reported at $2.0 million in Q4 2023.

• Receivables - Other for Q4 2023 came in at $2.0 million, up 70.51% year-over-year; the trailing twelve-month figure through Dec 2023 was $2.0 million (up 70.51% YoY), and the FY2023 annual result was $2.0 million, changed N/A from the prior year.
• Receivables - Other rose to $2.0 million in Q4 2023 per NBP's latest filing, from $1.2 million in the prior quarter.
• Over five years, Receivables - Other peaked at $43.5 million in Q2 2022 and troughed at $1.2 million in Q4 2022.
• A 5-year average of $18.0 million and a median of $4.9 million in 2021 frame the typical range for Receivables - Other.
• The sharpest annual moves came in 2020 and 2021: Receivables - Other surged 1392.78% in 2020, then slumped 85.6% in 2021.
• A 5-year view of Receivables - Other shows it stood at $2.3 million in 2019, then surged by 1392.78% to $34.3 million in 2020, then tumbled by 85.6% to $4.9 million in 2021, then tumbled by 76.58% to $1.2 million in 2022, then jumped by 70.51% to $2.0 million in 2023.
• Business Quant data shows NBP's Receivables - Other at $2.0 million in Q4 2023, $1.2 million in Q4 2022, and $43.5 million in Q2 2022.